Natalia A. Loktionova All publications ( 12 ) Fang Q. Loktionova NA. Moschel RC. Javanmard S. Pauly GT. Pegg AE. Differential inactivation of polymorphic variants of human O(6)-alkylguanine-DNA alkyltransferase. 2007 Oct 2. Biochem Pharmacol. . Javanmard S. Loktionova NA. Fang Q. Pauly GT. Pegg AE. Moschel RC. Inactivation of O(6)-alkylguanine-DNA alkyltransferase by folate esters of O(6)-benzyl-2'-deoxyguanosine and of O(6)-[4-(hydroxymethyl)benzyl]guanine. 2007 Oct 18. J Med Chem. 50(21):5193-201. Pegg AE. Fang Q. Loktionova NA. Human variants of O(6)-alkylguanine-DNA alkyltransferase. 2007 May 5. DNA Repair (Amst). . Nelson ME. Loktionova NA. Pegg AE. Moschel RC. 2-amino-O4-benzylpteridine derivatives: potent inactivators of O6-alkylguanine-DNA alkyltransferase. 2004 Jul 15. J Med Chem. 47(15):3887-91. Valadez JG. Liu L. Loktionova NA. Pegg AE. Guengerich FP. Activation of bis-electrophiles to mutagenic conjugates by human O6-alkylguanine-DNA alkyltransferase. 2004 Jul. Chem Res Toxicol. 17(7):972-82. National Institute of Environmental Health Sciences National Cancer Institute Liu L. Hachey DL. Valadez G. Williams KM. Guengerich FP. Loktionova NA. Kanugula S. Pegg AE. Characterization of a mutagenic DNA adduct formed from 1,2-dibromoethane by O6-alkylguanine-DNA alkyltransferase. 2004 Feb 6. J Biol Chem. 279(6):4250-9. National Institute of Environmental Health Sciences National Cancer Institute Choi U. DeRavin SS. Yamashita K. Whiting-Theobald N. Linton GF. Loktionova NA. Pegg AE. Malech HL. Nuclear-localizing O6-benzylguanine-resistant GFP-MGMT fusion protein as a novel in vivo selection marker. 2004 Aug. Exp Hematol. 32(8):709-19. Loktionova NA. Pegg AE. Interaction of mammalian O(6)-alkylguanine-DNA alkyltransferases with O(6)-benzylguanine. 2002 Apr 15. Biochem Pharmacol. 63(8):1431-42. National Cancer Institute Pegg AE. Goodtzova K. Loktionova NA. Kanugula S. Pauly GT. Moschel RC. Inactivation of human O(6)-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O(6)-benzylguanine. 2001 Mar. J Pharmacol Exp Ther. 296(3):958-65. National Cancer Institute Xu-Welliver M. Kanugula S. Loktionova NA. Crone TM. Pegg AE. Conserved residue lysine165 is essential for the ability of O6-alkylguanine-DNA alkyltransferase to react with O6-benzylguanine. 2000 Apr 15. Biochem J. 347(Pt 2):527-34. National Cancer Institute Loktionova NA. Xu-Welliver M. Crone TM. Kanugula S. Pegg AE. Protection of CHO cells by mutant forms of O6-alkylguanine-DNA alkyltransferase from killing by 1,3-bis-(2-chloroethyl)-1-nitrosourea (BCNU) plus O6-benzylguanine or O6-benzyl-8-oxoguanine. 1999 Jul 15. Biochem Pharmacol. 58(2):237-44. National Cancer Institute Loktionova NA. Pegg AE. Point mutations in human O6-alkylguanine-DNA alkyltransferase prevent the sensitization by O6-benzylguanine to killing by N,N'-bis (2-chloroethyl)-N-nitrosourea. 1996 Apr 1. Cancer Res. 56(7):1578-83. National Cancer Institute